{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:ladiratuzumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:cofetuzumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04155125: Phase 3 Interventional Completed Anaemia Associated With Chronic Kidney Disease
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03516981: Phase 2 Interventional Active, not recruiting Advanced Non-Small Cell Lung Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02754076: Phase 1/Phase 2 Interventional Completed MPS III B
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03188848: Phase 1 Interventional Unknown status Healthy Subject
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:mupadolimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04620811: Phase 3 Interventional Completed Eosinophilic Gastritis
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT02290951: Phase 1 Interventional Active, not recruiting Non-Hodgkin Lymphoma
(2015)
Source URL:
Class:
PROTEIN
